Neuphoria Therapeutics Inc. (NEUP) community

NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 18, 2026Score 5/30

$2.55−0.03 (-1.16%)

Close on Nov 13, 2026Market cap $76.66KP/E –Yield –

Community

Notes and questions about Neuphoria Therapeutics from other investors

No posts about NEUP yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Neuphoria Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2160 reverse split on Feb 14, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NEUP.

Compare: NEUP vs IGC · NEUP vs KRSA · NEUP vs DNTH · NEUP vs OVID · NEUP vs ATXI

Revenue growth-92.5% · median -46.7%

Operating margin-1401.1% · median -2843.5%

Net margin-1145.7% · median -1836.7%

Company	Revenue	Growth
OVID	$1.45M	-78.0%
NEUP	$1.17M	-92.5%
IGC	$1.12M	-15.4%
KRSA	–	–
DNTH	–	–
ATXI	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 7
Held by institutions: 36.8%
Auditor: Wolf & Company P.C.
SEC CIK: 1191070

Advertisement
300 × 250

See a number that looks wrong?